Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 3Gastrointestinal 3Sarcoma 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Pancreatic Neoplasms 84Carcinoma, Non-Small-Cell Lung 56Triple Negative Breast Neoplasms 35Breast Neoplasms 34Neoplasms 28Neoplasm Metastasis 28Colorectal Neoplasms 17Lung Neoplasms 13Carcinoma, Pancreatic Ductal 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Adenocarcinoma 9Stomach Neoplasms 8Melanoma 8Carcinoma 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms by Site 6Fallopian Tube Neoplasms 6Small Cell Lung Carcinoma 5Carcinoma, Squamous Cell 5Peritoneal Neoplasms 4Head and Neck Neoplasms 4Digestive System Neoplasms 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Solid Tumor 3Sarcoma 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Histologic Type 3

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Trishula Therapeutics, Inc.

Phase 1 Completed
185 enrolled 28 charts
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04742959 2024-04-26

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

TransThera Sciences (Nanjing), Inc.

Phase 1/2 Completed
203 enrolled
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡